Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9

Extra-cellular galectin-9 (gal-9) is an immuno-modulatory protein with predominant immunosuppressive effects. Inappropriate production of gal-9 has been reported in several human malignancies and viral diseases like nasopharyngeal, pancreatic and renal carcinomas, metastatic melanomas and chronic active viral hepatitis. Therefore therapeutic antibodies neutralizing extra-cellular gal-9 are expected to contribute to immune restoration in these pathological conditions. Two novel monoclonal antibodies targeting gal-9 –Gal-Nab 1 and 2—have been produced and characterized in this study. We report a protective effect of Gal-Nab1 and Gal-Nab2 on the apoptotic cell death induced by gal-9 in primary T cells. In addition, they inhibit late phenotypic changes observed in peripheral T cells that survive gal-9-induced apoptosis. Gal-Nab1 and Gal-Nab2 bind nearly identical, overlapping linear epitopes contained in the 213–224 amino-acid segments of gal-9. Nevertheless, they have some distinct functional characteristics suggesting that their three-dimensional epitopes are distinct. These differences are best demonstrated when gal-9 is applied on Jurkat cells where Gal-Nab1 is less efficient than Gal-Nab2 in the prevention of apoptotic cell death. In addition, Gal-Nab1 stimulates non-lethal phosphatidylserine translocation at the plasma membrane and calcium mobilization triggered by gal-9 in these cells. Both Gal-Nab1 and 2 cross-react with murine gal-9. They bind its natural as well as its recombinant form. This cross-species recognition will be an advantage for their assessment in pre-clinical tumor models.

[1]  D. Giguère,et al.  Synthetic Inhibitors of Galectins: Structures and Syntheses , 2018 .

[2]  Enrique Gallego-Colon,et al.  Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives , 2018, International journal of molecular sciences.

[3]  L. Zitvogel,et al.  Trial watch: Immune checkpoint blockers for cancer therapy , 2017, Oncoimmunology.

[4]  T. Niki,et al.  Regulatory T Cell–Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9 , 2017, The Journal of Immunology.

[5]  H. Rosen,et al.  Galectin‐9: Diverse roles in hepatic immune homeostasis and inflammation , 2017, Hepatology.

[6]  B. Ueberheide,et al.  Dectin-1 Activation on Macrophages by Galectin-9 Promotes Pancreatic Carcinoma and Peritumoral Immune-Tolerance , 2017, Nature Medicine.

[7]  E. Pocheć,et al.  On the trail of the glycan codes stored in cancer-related cell adhesion proteins. , 2017, Biochimica et biophysica acta. General subjects.

[8]  Y. Nishio,et al.  Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells , 2016, Cancer Immunology Research.

[9]  A. Leontovich,et al.  Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma , 2016, Melanoma research.

[10]  Shengdian Wang,et al.  Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. , 2016, Oncology letters.

[11]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  K. Akashi,et al.  A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. , 2015, Cell stem cell.

[13]  T. Niki,et al.  Impact of Exogenous Galectin-9 on Human T Cells , 2015, The Journal of Biological Chemistry.

[14]  T. Niki,et al.  19 Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells , 2015 .

[15]  Le Xu,et al.  Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma , 2015, Tumor Biology.

[16]  T. Niki,et al.  Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. , 2015, Journal of the National Cancer Institute.

[17]  T. Whiteside.  RE: Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells. , 2015, Journal of the National Cancer Institute.

[18]  O. Nüsse,et al.  Characterization of novel store-operated calcium entry effectors. , 2014, Biochimica et biophysica acta.

[19]  K. Mills,et al.  Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines , 2014, Oncogene.

[20]  Chuan Wu,et al.  Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. , 2014, Immunity.

[21]  M. F. Troncoso,et al.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. , 2013, World journal of gastroenterology.

[22]  A. Griffioen,et al.  Galectin-9 in tumor biology: a jack of multiple trades. , 2013, Biochimica et biophysica acta.

[23]  Jianrong Li,et al.  Galectin-9 Protein Is Up-regulated in Astrocytes by Tumor Necrosis Factor and Promotes Encephalitogenic T-cell Apoptosis* , 2013, The Journal of Biological Chemistry.

[24]  J. Bruneau,et al.  Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C , 2013, PLoS pathogens.

[25]  T. Niki,et al.  Galectin-9 Activates and Expands Human T-Helper 1 Cells , 2013, PloS one.

[26]  M. Hirashima,et al.  Self-association of the galectin-9 C-terminal domain via the opposite surface of the sugar-binding site. , 2013, Journal of biochemistry.

[27]  T. Niki,et al.  Cell Surface Galectin-9 Expressing Th Cells Regulate Th17 and Foxp3+ Treg Development by Galectin-9 Secretion , 2012, PloS one.

[28]  Yingying Zhang,et al.  Galectin-9 Ameliorates Con A-Induced Hepatitis by Inducing CD4+CD25low/int Effector T-Cell Apoptosis and Increasing Regulatory T Cell Number , 2012, PloS one.

[29]  W. Rosenberg,et al.  Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection , 2012, PloS one.

[30]  A. Ganser,et al.  IFN-γ Production by Allogeneic Foxp3+ Regulatory T Cells Is Essential for Preventing Experimental Graft-versus-Host Disease , 2012, The Journal of Immunology.

[31]  P. Opolon,et al.  A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses , 2012, Infectious Agents and Cancer.

[32]  T. Niki,et al.  Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. , 2012, Clinical immunology.

[33]  Benhur Lee,et al.  Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry , 2011, Proceedings of the National Academy of Sciences.

[34]  C. Baecher-Allan,et al.  Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease , 2011, Nature Medicine.

[35]  S. Sehrawat,et al.  Immunity and immunopathology to viruses: what decides the outcome? , 2010, Nature Reviews Immunology.

[36]  Jessica A. Randall,et al.  A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PloS one.

[37]  F. Breitling,et al.  Cloning of Variable Domains from Mouse Hybridoma by PCR , 2010 .

[38]  S. Stowell,et al.  Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. , 2009, Molecular biology of the cell.

[39]  T. Niki,et al.  Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. , 2009, Blood.

[40]  T. Niki,et al.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.

[41]  Lijun Xu,et al.  The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. , 2007, Cellular immunology.

[42]  A. Yamauchi,et al.  Characterization of galectin-9-induced death of Jurkat T cells. , 2006, Journal of biochemistry.

[43]  M. Hirashima,et al.  Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9 , 2006, BMC Cancer.

[44]  P. Stanley,et al.  Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. , 2006, Glycobiology.

[45]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[46]  M. Hirashima,et al.  Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectins , 2005, FEBS letters.

[47]  G. Berry,et al.  Induction of T helper type 1–like regulatory cells that express Foxp3 and protect against airway hyper-reactivity , 2004, Nature Immunology.

[48]  M. J. Abedin,et al.  Galectin-9 Induces Apoptosis Through the Calcium-Calpain-Caspase-1 Pathway1 , 2003, The Journal of Immunology.

[49]  M. J. Abedin,et al.  Selective Eosinophil Adhesion to Fibroblast Via IFN-γ-Induced Galectin-9 , 2002, The Journal of Immunology.

[50]  S. Yagihashi,et al.  Interferon‐γ stimulates the expression of galectin‐9 in cultured human endothelial cells , 2002, Journal of Leukocyte Biology.

[51]  S. Yagihashi,et al.  Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. , 2002, Journal of leukocyte biology.